{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:09:21Z","timestamp":1761610161354,"version":"build-2065373602"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venezuela experienced an interruption in antiretroviral therapy (ART) from 2016 to 2018. Although in early 2019, the dolutegravir (DTG) based regimens were implemented for HIV treatment in Venezuela, few studies have evaluated the efficacy of these regimens. This cross-sectional study describes the utilization, switches and efficacy of ART regimens in the main HIV outpatient care in Venezuela in 2024. Data from 1,998 patient records revealed that the dolutegravir\/lamivudine\/tenofovir (DTG\/3TC\/TDF) regimen was predominantly used (85.5%). A high viral suppression rate of over 90% was documented for all DTG-based regimens, with no significant difference found between the main regimen (DTG\/3TC\/TDF) and its alternatives: DTG\/emtricitabine\/tenofovir alafenamide (TAF), abacavir\/3TC\u2009+\u2009DTG and, DTG\/3TC. Overall, almost all switches (97.1%) were made toward DTG\/FTC\/TAF. Osteoporosis was the main reason for switching treatments (80.1%).<\/jats:p>","DOI":"10.1186\/s12981-025-00811-y","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:29:41Z","timestamp":1761568181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distribution and efficacy of dolutegravir-based regimens in the main HIV outpatient care in Caracas, Venezuela"],"prefix":"10.1186","volume":"22","author":[{"given":"Mar\u00eda F.","family":"Alvarado-Bruzual","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor A.","family":"Mendoza-Merlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus A.","family":"Martinez-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis J.","family":"Guerra-Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael N.","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"Carballo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Carolyn","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda E.","family":"Landaeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Forero-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"811_CR1","unstructured":"UNAIDS Data. 2024. In. Geneva: Joint United Nations Programme on HIV\/AIDS; 2024."},{"key":"811_CR2","unstructured":"UNAIDS Data. 2023. In. Geneva: Joint United Nations Programme on HIV\/AIDS; 2023: 250."},{"issue":"10177","key":"811_CR3","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/S0140-6736(19)30344-7","volume":"393","author":"KR Page","year":"2019","unstructured":"Page KR, Doocy S, Reyna Ganteaume F, Castro JS, Spiegel P, Beyrer C. Venezuela\u2019s public health crisis: a regional emergency. Lancet (London England). 2019;393(10177):1254\u201360.","journal-title":"Lancet (London England)"},{"issue":"5","key":"811_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bjid.2019.07.006","volume":"23","author":"MM de Lima Junior","year":"2019","unstructured":"de Lima Junior MM, Rodrigues GA, Lima MRD. Evaluation of emerging infectious disease and the importance of SINAN for epidemiological surveillance of Venezuelans immigrants in Brazil. Brazilian J Infect Dis. 2019;23(5):307\u201312.","journal-title":"Brazilian J Infect Dis"},{"key":"811_CR5","first-page":"e336","volume":"54","author":"O Molina Lubo","year":"2022","unstructured":"Molina Lubo O. Efectos de La migraci\u00f3n venezolana sobre La notificaci\u00f3n de Casos de VIH En Colombia. Rev Univ Ind Santander Salud. 2022;54:e336\u2013336.","journal-title":"Rev Univ Ind Santander Salud"},{"key":"811_CR6","doi-asserted-by":"crossref","unstructured":"Rebolledo-Ponietsky K, Munayco CV, Mezones-Holgu\u00edn E. Migration crisis in venezuela: impact on HIV in Peru. J Travel Med 2019, 26(2).","DOI":"10.1093\/jtm\/tay155"},{"key":"811_CR7","unstructured":"PAHO W, UNAIDS, Gobierno Bolivariano de venezuela: plan maestro Para El fortalecimiento de La respuesta al VIH, La tuberculosis y La malaria En La Rep\u00fablica Bolivariana de Venezuela desde Una perspectiva de Salud p\u00fablica. In.: Organizaci\u00f3n Mundial de la Salud (OMS); 2018."},{"issue":"6","key":"811_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/hiv.13050","volume":"22","author":"YS Punekar","year":"2021","unstructured":"Punekar YS, Parks D, Joshi M, Kaur S, Evitt L, Chounta V, Radford M, Jha D, Ferrante S, Sharma S, et al. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta\u2010analysis of real\u2010world evidence. HIV Med. 2021;22(6):423\u201333.","journal-title":"HIV Med"},{"issue":"3","key":"811_CR9","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.24875\/AIDSRev.20000103","volume":"23","author":"Y Shu","year":"2021","unstructured":"Shu Y, Qiu C, Tu X, Deng Z, Deng Y, Wang H, Zhao X, Shi Z. Efficacy and safety of triple versus Dolutegravir-based dual therapy in patients with HIV-1 infection: A Meta-analysis of randomized controlled trials. AIDS Rev. 2021;23(3):6467.","journal-title":"AIDS Rev"},{"issue":"9","key":"811_CR10","doi-asserted-by":"publisher","first-page":"e0222229","DOI":"10.1371\/journal.pone.0222229","volume":"14","author":"M Cruciani","year":"2019","unstructured":"Cruciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected Naive patients: A systematic review and meta-analysis. PLoS ONE. 2019;14(9):e0222229.","journal-title":"PLoS ONE"},{"issue":"1","key":"811_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12981-025-00700-4","volume":"22","author":"JA Morgado","year":"2025","unstructured":"Morgado JA, Medina MG, Guevara RN, Carballo M, Torres JR, Carri\u00f3n-Nessi FS, Forero-Pe\u00f1a DA. Brief communication: gaps and opportunities in HIV research in Venezuela. AIDS Res Therapy. 2025;22(1):5.","journal-title":"AIDS Res Therapy"},{"issue":"2","key":"811_CR12","first-page":"82","volume":"44","author":"A Gonz\u00e1lez-Delatorre","year":"2024","unstructured":"Gonz\u00e1lez-Delatorre A, Navas D, Mantilla E, Vielma S, Dugarte G, Silva N, Guzm\u00e1n S. Ter\u00e1n-\u00c1ngel gjrdlsvdm: Caracter\u00edsticas virol\u00f3gicas e inmunitarias de Pacientes Con VIH Que recibieron terapia antirretroviral Con TLD En El periodo 2020\u20132022. Estado T\u00e1chira Venezuela. 2024;44(2):82\u20137.","journal-title":"Estado T\u00e1chira Venezuela"},{"issue":"1","key":"811_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12879-023-08967-6","volume":"24","author":"DA Forero-Pe\u00f1a","year":"2024","unstructured":"Forero-Pe\u00f1a DA, Carri\u00f3n-Nessi FS, Forero-Pe\u00f1a JL, Camejo-\u00c1vila NA, Mendoza-Mill\u00e1n DL, Oma\u00f1a-\u00c1vila \u00d3D, Maricuto AL, Vel\u00e1squez VL, Mej\u00eda-Bernard MD, Rodriguez-Saavedra CM, et al. The impact of the COVID-19 pandemic on people living with HIV: a cross-sectional study in Caracas, Venezuela. BMC Infect Dis. 2024;24(1):87.","journal-title":"BMC Infect Dis"},{"key":"811_CR14","volume-title":"Tratamiento antirretroviral Para personas Con VIH - Gu\u00eda Pr\u00e1ctica 2020","author":"OPS ONUSIDA","year":"2020","unstructured":"ONUSIDA OPS, OMS. Tratamiento antirretroviral Para personas Con VIH - Gu\u00eda Pr\u00e1ctica 2020. In. Caracas: Programa Conjunto de las Naciones Unidas sobre el VIH\/Sida; 2020."},{"issue":"9936","key":"811_CR15","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","volume":"383","author":"B Clotet","year":"2014","unstructured":"Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, et al. Once-daily dolutegravir versus Darunavir plus Ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet (London England). 2014;383(9936):2222\u201331.","journal-title":"Lancet (London England)"},{"issue":"9868","key":"811_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet (London England). 2013;381(9868):735\u201343.","journal-title":"Lancet (London England)"},{"issue":"3","key":"811_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","volume":"19","author":"M Aboud","year":"2019","unstructured":"Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, Losso MH, Chetchotisakd P, Brites C, Sievers J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19(3):253\u201364.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"811_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"NI Paton","year":"2021","unstructured":"Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Kaimal A, Mirembe G, Tukamushabe P, Ategeka G, et al. Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV. N Engl J Med. 2021;385(4):330\u201341.","journal-title":"N Engl J Med"},{"key":"811_CR19","unstructured":"ONUSIDA. Informes nacionales sobre Avances En respuesta al sida - Venezuela (Rep\u00fablica Bolivariana de). Monitoreo global Del Sida 2019. Ginebra. Programa Conjunto de las Naciones Unidas sobre el VIH\/Sida; 2019."},{"key":"811_CR20","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; 2024."},{"issue":"2","key":"811_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/COH.0000000000000527","volume":"14","author":"M Vitoria","year":"2019","unstructured":"Vitoria M, Rangaraj A, Ford N, Doherty M. Current and future priorities for the development of optimal HIV drugs. Curr Opin HIV AIDS. 2019;14(2):143\u20139.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"811_CR22","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"WDF Venter","year":"2020","unstructured":"Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, et al. Dolutegravir with emtricitabine and Tenofovir Alafenamide or Tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and Tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666\u201376.","journal-title":"Lancet HIV"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00811-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:03:20Z","timestamp":1761609800000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00811-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00811-y","relation":{},"ISSN":["1742-6405"],"issn-type":[{"type":"electronic","value":"1742-6405"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the University Hospital of Caracas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}